JS-K was designed as a novel cancer therapeutic agent that releases nitric oxide (NO) when activated by GSTs; this pro-drug has shown promise for the treatment of multiple malignancies, including breast cancer and leukemias (20, 26). This evidence concerns the gene HPGDS and breast carcinoma.